Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

22.39 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Pfizer Declares Second-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
Mr. Ethan Billings recommends paying close attention to biotech stocks
Via Binary News Network
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
From Pfizer Inc.
Via Business Wire
Milestone Merger Payment with Predictive Oncology to Advance AI-Driven Biomarker Discovery & Precision Medicine in Cancer & Beyond: Stock Symbol: RENB
$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAILOS ANGELES - March 3, 2025 - PRLog -- Developing AI and Biotechnology Platforms for Early... 
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Exposures Product Safety
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
SaveRxCanada.to Offers Affordable Access to Palbociclib (Ibrance) from India
April 14, 2025 -- Breast Cancer Patients Can Save Thousands Monthly with Trusted Generic "Palnat" at Just $4.38 Per Capsule 
Via 24-7 Press Release
Topics Supply Chain
Exposures Supply Chain
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
From Pfizer Inc.
Via Business Wire
50 or Older? The Pneumococcal Pneumonia Vaccine is Recommended for You
Via StatePoint Media
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
From Pfizer Inc.
Via Business Wire
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed 
Via TheNewswire.com
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
From Pfizer Inc.
Via Business Wire
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
From Pfizer Inc.
Via Business Wire
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
From Pfizer Inc.
Via Business Wire
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
From Pfizer Inc.
Via Business Wire
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
From Pfizer Inc.
Via Business Wire
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.